Clinical trials: SBRT
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma.
- Trial name
- NCT05626569
- Testing
- PD-1 combined with SBRT
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Benign Prostatic Hyperplasia
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia.
- Trial name
- NCT05148156
- Testing
- Urolift
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Lung Cancer, Lung Cancer Screening
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test.
- Conditions
- Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers
- Trial name
- NCT07008664
- Testing
- Epigenetic Signature Assay
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hepatocellular Carcinoma
Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy
Respiratory-gated, volumetric-modulated arc therapy will be used for the clinical development of high dose rate Stereotactic Body Radiotherapy (SBRT) in inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT01850316
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Radiotherapy Side Effect
SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer
Human recombinant endostatin preclinical studies have shown that the drug can inhibit endothelial cell proliferation, angiogenesis and tumor growth, still can directly induce lung cancer cell apoptosis, multiple clinical studies…
- Trial name
- SBRTLCES (NCT04274270)
- Testing
- Endostar
- Where
- 16 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Hepatocellular Carcinoma
A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC
The trial is a multicentre, prospective, randomised controlled, unblinded, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of inoperable HCC treated with a TAE/TACE incomplete cycle.
- Trial name
- NCT02323360
- Testing
- SBRT, TACE
- Where
- Italy
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma
Hypothesis: Patients with hepatocellular carcinoma (HCC) have few options if they fail or are unable to undertake surgery, transarterial chemoembolization (TACE) and/or chemotherapy.
- Trial name
- TACERT (NCT03079778)
- Testing
- transarterial chemoembolization, TACE plus RT
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatocellular Carcinoma
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC patients already have advanced disease.
- Trial name
- NCT04193696
- Testing
- Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Lymph Node Cancer Metastatic
High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients
This is a prospective, multicentric, phase II and feasibility study aimed to address early and late side effects of hypofractionated ablative radiotherapy for oligometastatic patients with lymph node metastases for…
- Trial name
- NCT02570399
- Testing
- Oligometastatic patients with abdominal-pelvic lymph nodes
- Where
- Italy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Solid Tumor, Adult
Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS)
A prospective study evaluating prone and supine positioning for radiation planning of spine Cyberknife radiotherapy treatment. Patients with tumours in which PTV coverage is compromised due to tumour geography, including…
- Trial name
- IMPRESS (NCT05252975)
- Testing
- Setup and Imaging for at CT radiation planning
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Metabolomic Study for Localized Prostate Cancer
Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease.
- Trial name
- NCT01968538
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Uveal Melanoma
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma.
- Trial name
- NCT03712904
- Testing
- Stereotactic Body Radiation Therapy, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Nasopharyngeal Cancinoma (NPC), SBRT
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by…
- Conditions
- Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
- Trial name
- NCT06676722
- Testing
- SBRT combined with Nimotuzumab followed by Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Kidney Neoplasm, Renal Cancer
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer
- Conditions
- Kidney Neoplasm, Renal Cancer, Inoperable Disease, SBRT
- Trial name
- SABINA (NCT05817604)
- Testing
- SBRT
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Consorci Sanitari de Terrassa
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Iadademstat + SBRT With Atezo in ES-SCLC
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor…
- Trial name
- TIARA (NCT07113691)
- Testing
- Iadademstat, Atezolizumab, SBRT
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Pancreatic Cancer
A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
The purpose of this study is to find out the maximum dose of SBRT that can be safely given after chemotherapy for treatment of pancreatic cancer that cannot be removed surgically.
- Trial name
- NCT02643498
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- 7 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bone Metastases
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases
To compare increasing doses and different treatment schedules of stereotactic body radiation therapy (SBRT) against standard treatment scheduling.
- Trial name
- NCT06065449
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
MR-Linac for Head and Neck SBRT
This study will evaluate the feasibility and safety of using MR-guided adaptive Head and Neck stereotactic radiotherapy (SBRT) at each fraction on the 1.5T MR-Linac.
- Trial name
- NCT04809792
- Testing
- SBRT on the MR-Linac
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- NCT05451173
- Testing
- Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Alexander Chi